Teleflex (NYSE:TFX) Rating Increased to Strong-Buy at BMO Capital Markets

Teleflex (NYSE:TFXGet Free Report) was upgraded by equities research analysts at BMO Capital Markets to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

TFX has been the subject of a number of other reports. Piper Sandler upgraded shares of Teleflex from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $140.00 to $160.00 in a research note on Monday, June 8th. Bank of America upgraded shares of Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price objective on the stock in a research report on Monday, April 13th. Truist Financial restated a “hold” rating and issued a $143.00 target price (up from $135.00) on shares of Teleflex in a report on Monday, May 11th. Mizuho set a $140.00 target price on shares of Teleflex in a research report on Friday, May 8th. Finally, Wall Street Zen upgraded shares of Teleflex from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $147.44.

Get Our Latest Report on TFX

Teleflex Price Performance

NYSE TFX opened at $134.16 on Wednesday. Teleflex has a one year low of $100.18 and a one year high of $139.67. The stock has a 50-day moving average of $129.72 and a 200 day moving average of $119.99. The company has a market capitalization of $5.94 billion, a price-to-earnings ratio of -5.88, a PEG ratio of 0.97 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.03 and a current ratio of 2.55.

Teleflex (NYSE:TFXGet Free Report) last issued its earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.18. The business had revenue of $548.30 million during the quarter, compared to analyst estimates of $536.91 million. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.Teleflex’s revenue was up 32.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.44 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, sell-side analysts forecast that Teleflex will post 6.7 EPS for the current year.

Hedge Funds Weigh In On Teleflex

A number of institutional investors have recently bought and sold shares of the stock. Ruffer LLP purchased a new stake in Teleflex in the fourth quarter worth about $5,154,000. Waterfront Wealth Inc. purchased a new position in shares of Teleflex during the 4th quarter valued at about $2,050,000. Eos Management L.P. bought a new position in shares of Teleflex during the 4th quarter valued at approximately $3,763,000. Capital International Investors bought a new position in shares of Teleflex during the 3rd quarter valued at approximately $44,851,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Teleflex by 227.5% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 27,822 shares of the medical technology company’s stock worth $3,395,000 after acquiring an additional 19,327 shares in the last quarter. 95.62% of the stock is owned by institutional investors.

Teleflex Company Profile

(Get Free Report)

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.

Read More

Analyst Recommendations for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.